BioArctic Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

BioArctic wird ein jährliches Gewinn- und Umsatzwachstum von 118.7% bzw. 49.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 63.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 40.2% betragen.

Wichtige Informationen

118.7%

Wachstumsrate der Gewinne

63.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	49.4%
Wachstumsrate der Einnahmen	49.2%
Zukünftige Eigenkapitalrendite	40.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Sep 16

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Apr 04

Gewinn- und Umsatzwachstumsprognosen

OM:BIOA B - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,634	1,021	505	515	6
12/31/2025	881	246	382	286	6
12/31/2024	243	-267	-317	-307	2
9/30/2024	167	-233	-169	-162	N/A
6/30/2024	299	-88	-142	-134	N/A
3/31/2024	252	-122	-111	-104	N/A
12/31/2023	616	229	302	310	N/A
9/30/2023	607	259	111	124	N/A
6/30/2023	617	270	284	289	N/A
3/31/2023	619	327	294	307	N/A
12/31/2022	229	-11	-44	-32	N/A
9/30/2022	232	28	-15	-13	N/A
6/30/2022	18	-147	-170	-159	N/A
3/31/2022	21	-135	-147	-143	N/A
12/31/2021	26	-120	-145	-140	N/A
9/30/2021	30	-114	-138	-128	N/A
6/30/2021	37	-97	-114	-103	N/A
3/31/2021	34	-101	-106	-93	N/A
12/31/2020	65	-69	-105	-92	N/A
9/30/2020	84	-72	-125	-120	N/A
6/30/2020	93	-60	-163	-160	N/A
3/31/2020	252	78	-46	-43	N/A
12/31/2019	283	88	324	327	N/A
9/30/2019	779	441	286	292	N/A
6/30/2019	852	475	305	310	N/A
3/31/2019	729	380	171	176	N/A
12/31/2018	722	382	-204	-200	N/A
9/30/2018	257	58	-161	-157	N/A
6/30/2018	197	32	N/A	-149	N/A
3/31/2018	194	29	N/A	-139	N/A
12/31/2017	157	15	N/A	-135	N/A
9/30/2017	193	78	N/A	616	N/A
6/30/2017	160	71	N/A	630	N/A
3/31/2017	127	64	N/A	647	N/A
12/31/2016	106	58	N/A	675	N/A
12/31/2015	42	4	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIOA B wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: BIOA B wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: BIOA B wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: BIOA BDie Einnahmen des Unternehmens (49.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0.07% pro Jahr).

Hohe Wachstumseinnahmen: BIOA BDie Einnahmen des Unternehmens (49.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIOA BDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (40.2%).

BioArctic Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Price target decreased by 8.6% to kr336

Consensus EPS estimates increase by 112%

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 16%

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Price target decreased by 8.6% to kr336

New major risk - Share price stability

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Consensus EPS estimates fall by 60%

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Consensus forecasts updated

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Consensus forecasts updated

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease